|
1
|
Citri A and Yarden Y: EGF-ERBB signaling:
towards the systems level. Nat Rev Mol Cell Biol. 7:505–516. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Landgraf R: HER2 (ERBB2)-functional
diversity from structurally conserved building blocks. Breast
Cancer Res. 9:2022007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Slamon DJ, Clark GM, Wong SG, et al: Human
breast cancer: correlation of relapse and survival with
amplification of the HER-2/neu oncogene. Science. 235:177–182.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Esteva F, Yu D, Hung M and Hortobagyi G:
Molecular predictors of response to trastuzumab and lapatinib in
breast cancer. Nat Rev Clin Oncol. 2:98–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rusnak DW, Lackey K, Affleck K, et al: The
effects of the novel, reversible epidermal growth factor
receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of
human normal and tumor-derived cell lines in vitro and in vivo. Mol
Cancer Ther. 1:85–94. 2001.
|
|
6
|
Ma C, Niu X, Luo J, Shao Z and Shen K:
Combined effects of lapatinib and bortezomib in human epidermal
receptor 2 (HER2)-overexpressing breast cancer cells and activity
of bortezomib against lapatinib-resistant breast cancer cells.
Cancer Sci. 10:2220–2226. 2010. View Article : Google Scholar
|
|
7
|
Konecny GE, Pegram MD, Venkatesan N, et
al: Activity of the dual kinase inhibitor lapatinib (GW572016)
against HER-2-overexpressing and trastuzumab-treated breast cancer
cells. Cancer Res. 66:1630–1639. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Geyer CE, Forster J, Lindquist D, et al:
Lapatinib plus capecitabine for HER2-positive advanced breast
cancer. N Engl J Med. 355:2733–2743. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johnston S, Pippen J Jr, Pivot X, et al:
Lapatinib combined with letrozole versus letrozole and placebo as
first-line therapy for postmenopausal hormone receptor-positive
metastatic breast cancer. J Clin Oncol. 27:5538–5546. 2009.
View Article : Google Scholar
|
|
10
|
Ghosh S, May MJ and Kopp EB: NF-κB and Rel
proteins: evolutionarily conserved mediators of immune responses.
Annu Rev Immunol. 16:225–260. 1998.
|
|
11
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 3:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng C, Yin Q and Wu H: Structural
studies of NF-κB signaling. Cell Res. 1:183–195. 2011.
|
|
13
|
Biswas DK, Shi Q, Baily S, et al: NF-κB
activation in human breast cancer specimens and its role in cell
proliferation and apoptosis. Proc Natl Acad Sci USA.
101:10137–10142. 2004.
|
|
14
|
Merkhofer E, Cogswell P and Baldwin A:
Her2 activates NF-κB and induces invasion through the canonical
pathway involving IKKα. Oncogene. 8:1238–1248. 2010.
|
|
15
|
Liu M, Ju X, Willmarth N, et al: Nuclear
factor-κB enhances ErbB2-induced mammary tumorigenesis and
neoangiogenesis in vivo. Am J Pathol. 5:1910–1920. 2009.
|
|
16
|
Montagut C, Tusquets I, Ferrer B, et al:
Activation of nuclear factor-κB is linked to resistance to
neoadjuvant chemotherapy in breast cancer patients. Endocr Relat
Cancer. 2:607–616. 2006.
|
|
17
|
Manna S, Manna P and Sarkar A: Inhibition
of RelA phosphorylation sensitizes apoptosis in constitutive
NF-kappaB-expressing and chemoresistant cells. Cell Death Differ.
1:158–170. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
deGraffenried L, Chandrasekar B,
Friedrichs W, et al: NF-κB inhibition markedly enhances sensitivity
of resistant breast cancer tumor cells to tamoxifen. Ann Oncol.
15:885–890. 2004.
|
|
19
|
Papanikolaou V, Iliopoulos D, Dimou I, et
al: Survivin regulation by HER2 through NF-κB and c-myc in
irradiated breast cancer cells. J Cell Mol Med. 7:1542–1550.
2011.
|
|
20
|
Rivas M, Tkach M, Beguelin W, et al:
Transactivation of ErbB-2 induced by tumor necrosis factor α
promotes NF-κB activation and breast cancer cell proliferation.
Breast Cancer Res Treat. 122:111–124. 2010.
|
|
21
|
Guo G, Wang T, Gao Q, et al: Expression of
ErbB2 enhances radiation-induced NF-κB activation. Oncogene.
23:535–545. 2004.PubMed/NCBI
|
|
22
|
LaBonte M, Wilson P, Fazzone W, et al: The
dual EGFR/HER2 inhibitor lapatinib synergistically enhances the
antitumor activity of the histone deacetylase inhibitor
panobinostat in colorectal cancer models. Cancer Res. 10:3635–3648.
2011. View Article : Google Scholar
|
|
23
|
Liu L, Greger J, Shi H, et al: Novel
mechanism of lapatinib resistance in HER2-positive breast tumor
cells: activation of AXL. Cancer Res. 69:6871–6878. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aird K, Ghanayem R, Peplinski S, Lyerly H
and Devi G: X-Linked inhibitor of apoptosis protein inhibits
apoptosis in inflammatory breast cancer cells with acquired
resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol Cancer
Ther. 5:1432–1442. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang C, Park C, Hilsenbeck S, et al: β1
Integrin mediates an alternative survival pathway in breast cancer
cells resistant to lapatinib. Breast Cancer Res. 4:R842011.
|
|
26
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miyakoshi J and Yagi K: Inhibition of
IκB-α phosphorylation at serine and tyrosine acts independently on
sensitization to DNA damaging agents in human glioma cells. Br J
Cancer. 1:28–33. 2000.
|
|
28
|
Wu H, Li W, Wang T, Shu Y and Liu P:
Paeoniflorin suppress NF-κB activation through modulation of IκBα
and enhances 5-fluorouracil-induced apoptosis in human gastric
carcinoma cells. Biomed Pharmacother. 9:659–666. 2008.
|
|
29
|
Salminen A and Kaarniranta K:
Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-κB
signaling. Cell Signal. 4:573–577. 2010.PubMed/NCBI
|
|
30
|
Romashkova JA and Makarov SS: NF-κB is a
target of AKT in anti-apoptotic PDGF signalling. Nature. 401:86–90.
1999.
|
|
31
|
Madrid L, Mayo M, Reuther J and Baldwin A:
Akt stimulates the transactivation potential of the RelA/p65subunit
of NF-κB through utilization of the IκB kinase and activation of
the mitogen-activated protein kinase p38. J Biol Chem.
22:18934–18940. 2001.
|
|
32
|
Dan H, Cooper M, Cogswell P, Duncan J,
Ting J and Baldwin A: Akt-dependent regulation of NF-κB is
controlled by mTOR and Raptor in association with IKK. Genes Dev.
11:1490–1500. 2008.
|
